应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02157 乐普生物-B
耶稣受难节休市 03-28 16:08:03
3.190
+0.040
+1.27%
最高
3.260
最低
3.090
成交量
61.60万
今开
3.160
昨收
3.150
日振幅
5.40%
总市值
52.94亿
流通市值
51.21亿
总股本
16.59亿
成交额
196.99万
换手率
0.04%
流通股本
16.05亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
乐普生物-B(02157.HK)公布年度业绩 取得突破性收入 亏损大幅减少约96.8%
金融界 · 03-28 09:56
乐普生物-B(02157.HK)公布年度业绩 取得突破性收入 亏损大幅减少约96.8%
业务开发及商业化取得突破 乐普生物-B(02157)2023年度收入暴涨1347%至2.25亿元
智通财经 · 03-27 23:33
业务开发及商业化取得突破 乐普生物-B(02157)2023年度收入暴涨1347%至2.25亿元
乐普生物-B03月27日主力资金流入71万元 连续3日加仓
自选股智能写手 · 03-27 16:16
乐普生物-B03月27日主力资金流入71万元 连续3日加仓
乐普生物-B03月18日主力资金流入2万元 连续3日加仓
自选股智能写手 · 03-18
乐普生物-B03月18日主力资金流入2万元 连续3日加仓
乐普生物-B(02157.HK)3月27日举行董事会会议考虑及批准年度业绩
格隆汇资讯 · 03-15
乐普生物-B(02157.HK)3月27日举行董事会会议考虑及批准年度业绩
乐普生物-B盘中异动 下午盘大幅下挫5.32%
自选股智能写手 · 03-15
乐普生物-B盘中异动 下午盘大幅下挫5.32%
乐普生物-B尾盘涨逾10% 治疗胰腺癌候选药物获美国授予快速通道资格
新浪港股 · 03-14
乐普生物-B尾盘涨逾10% 治疗胰腺癌候选药物获美国授予快速通道资格
港股异动 | 乐普生物-B(02157)尾盘涨超13% 治疗胰腺癌候选药物获美国授予快速通道资格
智通财经 · 03-14
港股异动 | 乐普生物-B(02157)尾盘涨超13% 治疗胰腺癌候选药物获美国授予快速通道资格
乐普生物-B(02157)上涨10.61%,报3.65元/股
金融界 · 03-14
乐普生物-B(02157)上涨10.61%,报3.65元/股
乐普生物-B(02157)股价上升9.091%,现价港币$3.6
阿斯达克财经 · 03-14
乐普生物-B(02157)股价上升9.091%,现价港币$3.6
乐普生物-B盘中异动 股价大涨6.36%
自选股智能写手 · 03-14
乐普生物-B盘中异动 股价大涨6.36%
乐普生物-B(02157)下跌5.26%,报3.24元/股
金融界 · 03-13
乐普生物-B(02157)下跌5.26%,报3.24元/股
乐普生物-B盘中异动 急速跳水5.26%
自选股智能写手 · 03-13
乐普生物-B盘中异动 急速跳水5.26%
乐普生物-B盘中异动 早盘大幅上涨5.92%报3.581港元
自选股智能写手 · 03-12
乐普生物-B盘中异动 早盘大幅上涨5.92%报3.581港元
乐普生物-B(02157.HK)MRG004A获FDA快速通道资格,孤儿药认证提升治疗潜力
和讯网 · 03-11
乐普生物-B(02157.HK)MRG004A获FDA快速通道资格,孤儿药认证提升治疗潜力
乐普生物-B(02157.HK)治疗胰腺癌候选药物获美国授予快速通道资格
阿斯达克财经 · 03-11
乐普生物-B(02157.HK)治疗胰腺癌候选药物获美国授予快速通道资格
【港股通】乐普生物-B(02157)MRG004A用于治疗胰腺癌获FDA授予快速通道资格
金吾财讯 · 03-11
【港股通】乐普生物-B(02157)MRG004A用于治疗胰腺癌获FDA授予快速通道资格
乐普生物-B(02157):MRG004A 用于治疗胰腺癌获FDA授予快速通道资格
智通财经 · 03-11
乐普生物-B(02157):MRG004A 用于治疗胰腺癌获FDA授予快速通道资格
乐普生物-B盘中异动 股价大涨5.23%报3.421港元
自选股智能写手 · 03-06
乐普生物-B盘中异动 股价大涨5.23%报3.421港元
乐普生物-B(02157)股价下跌8.215%,现价港币$3.24
阿斯达克财经 · 03-05
乐普生物-B(02157)股价下跌8.215%,现价港币$3.24
加载更多
公司概况
公司名称:
乐普生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"02157","market":"HK","secType":"STK","nameCN":"乐普生物-B","latestPrice":3.19,"timestamp":1711613283015,"preClose":3.15,"halted":0,"volume":616000,"delay":0,"floatShares":1605176474,"shares":1659444838,"eps":-0.45303598,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":0.04,"latestTime":"03-28 16:08:03","open":3.16,"high":3.26,"low":3.09,"amount":1969930,"amplitude":0.053968,"askPrice":3.2,"askSize":8000,"bidPrice":3.16,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":-0.3236536943544474,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1645545600000,"adjPreClose":3.15,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":0.8912037035103002,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02157","defaultTab":"news","newsList":[{"id":"2422096869","title":"乐普生物-B(02157.HK)公布年度业绩 取得突破性收入 亏损大幅减少约96.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422096869","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422096869?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:56","pubTimestamp":1711590979,"startTime":"0","endTime":"0","summary":"乐普生物-B公布截至2023年12月31日止年度业绩,公司收入由上年度的约人民币0.16亿元增加至约人民币2.25亿元,增加约1347.2%。公司归母口径的亏损大幅减少约96.8%,由上年度的约人民币6.89亿元减少至该年度的约人民币0.22亿元。于报告期内,公司录得突破性收入,且产品管线及业务营运取得重大进展。集团BD收入及后续技术服务收入约人民币1.24亿元,普佑恒商业化收入约人民币1.01亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032809573387be4bd4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032809573387be4bd4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422125399","title":"业务开发及商业化取得突破 乐普生物-B(02157)2023年度收入暴涨1347%至2.25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422125399","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422125399?lang=zh_cn&edition=full","pubTime":"2024-03-27 23:33","pubTimestamp":1711553582,"startTime":"0","endTime":"0","summary":"智通财经APP讯,乐普生物-B 披露2023年年度业绩公告,该集团报告期实现收入2.25亿元,同比大涨1347.2%。毛利1.97亿元,同比大涨1352.6%。业务开发活动的许可收入:报告期内,该集团实现总收入约1.24亿元,该金额有关KYM与AstraZeneca于2023年2月23日就开发及商业化CMG901订立的许可协议。根据许可协议,公司已自KYM收取约1.10亿元作为许可收入,余下的收入来自AstraZeneca。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272341048b6a2fae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272341048b6a2fae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422959138","title":"乐普生物-B03月27日主力资金流入71万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2422959138","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422959138?lang=zh_cn&edition=full","pubTime":"2024-03-27 16:16","pubTimestamp":1711527387,"startTime":"0","endTime":"0","summary":"03月27日, 乐普生物-B股价涨2.94%,报收3.15元,成交金额351万元,换手率0.07%,振幅4.58%,量比1.75。乐普生物-B今日主力资金净流入71万元,连续3日净流入,上一交易日主力净流入29万元,今日环比增加144.83%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为25.00%,平均涨幅为5.78%。该股近5个交易日下跌0.32%,主力资金累计净流入69万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入224万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271617138b68e494&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271617138b68e494&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420441915","title":"乐普生物-B03月18日主力资金流入2万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2420441915","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420441915?lang=zh_cn&edition=full","pubTime":"2024-03-18 16:16","pubTimestamp":1710749761,"startTime":"0","endTime":"0","summary":"03月18日, 乐普生物-B股价跌3.25%,报收3.27元,成交金额332万元,换手率0.06%,振幅7.99%,量比0.56。乐普生物-B今日主力资金净流入2万元,连续3日净流入,上一交易日主力净流入32万元,今日环比减少93.75%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为33.33%,平均涨幅为5.78%。该股近5个交易日下跌2.37%,主力资金累计净流入139万元;近20日主力资金累计净流入139万元,其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031816164187922a2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031816164187922a2b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419944706","title":"乐普生物-B(02157.HK)3月27日举行董事会会议考虑及批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2419944706","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2419944706?lang=zh_cn&edition=full","pubTime":"2024-03-15 16:48","pubTimestamp":1710492523,"startTime":"0","endTime":"0","summary":"格隆汇3月15日丨乐普生物-B(02157.HK)宣布,董事会会议将于2024年3月27日(星期三)举行,藉以(其中包括)考虑及批准公司及其附属公司截至2023年12月31日止年度的年度业绩及其发布,并考虑建议派发末期股息(如有),以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151648538b36bce1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151648538b36bce1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419091499","title":"乐普生物-B盘中异动 下午盘大幅下挫5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419091499","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419091499?lang=zh_cn&edition=full","pubTime":"2024-03-15 14:30","pubTimestamp":1710484210,"startTime":"0","endTime":"0","summary":"2024年03月15日下午盘14时30分,乐普生物-B股票出现异动,股价急速下挫5.32%。截至发稿,该股报3.381港元/股,成交量64.2万股,换手率0.04%,振幅5.88%。乐普生物-B股票所在的生物技术行业中,整体跌幅为1.52%。其相关个股中,圣诺医药-B、绿竹生物-B、东曜药业-B涨幅较大,振幅较大的相关个股有基石药业-B、圣诺医药-B、宜明昂科-B,振幅分别为19.59%、19.03%、18.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240315143010861de921&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240315143010861de921&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419762506","title":"乐普生物-B尾盘涨逾10% 治疗胰腺癌候选药物获美国授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2419762506","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2419762506?lang=zh_cn&edition=full","pubTime":"2024-03-14 15:53","pubTimestamp":1710402812,"startTime":"0","endTime":"0","summary":"乐普生物-B(02157)尾盘上涨9.69%,现报3.62港元,成交额1069.05万港元。\n 乐普生物近日公布,其候选药物MRG004A (一种新型靶向组织因子的特异性抗体药物偶联物),已获美国食品药品监督管理局(FDA)授予快速通道资格(FTD),用于治疗胰腺癌。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-14/doc-inanhqvs7779359.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-14/doc-inanhqvs7779359.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419623319","title":"港股异动 | 乐普生物-B(02157)尾盘涨超13% 治疗胰腺癌候选药物获美国授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2419623319","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2419623319?lang=zh_cn&edition=full","pubTime":"2024-03-14 15:39","pubTimestamp":1710401997,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,乐普生物-B(02157)尾盘涨超13%,截至发稿,涨9.09%,报3.6港元,成交额1049.21万港元。消息面上,乐普生物近日公布,其候选药物MRG004A (一种新型靶向组织因子的特异性抗体药物偶联物),已获美国食品药品监督管理局(FDA)授予快速通道资格(FTD),用于治疗胰腺癌。据悉,MRG004A是一种新型靶向组织因子的特异性抗体药物偶联物,目前在美国及中国进行I/II期临床研究。公司已观察到胰腺癌、三阴性乳腺癌及宫颈癌的抗肿瘤活性信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1086385.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419764408","title":"乐普生物-B(02157)上涨10.61%,报3.65元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419764408","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419764408?lang=zh_cn&edition=full","pubTime":"2024-03-14 14:36","pubTimestamp":1710398211,"startTime":"0","endTime":"0","summary":"3月14日,乐普生物-B(02157)盘中上涨10.61%,截至14:36,报3.65元/股,成交787.82万元。乐普生物科技股份有限公司是一家专注于肿瘤治疗领域的创新型生物制药企业,主要通过自主创新和战略合作构建有市场差异化的生物药产品管线,并致力于建立并加强自主生产能力,实现产品的国内商业化和国际市场推广。截至2023年中报,乐普生物-B营业总收入1.54亿元、净利润-1.42亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/14143639849531.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419424346","title":"乐普生物-B(02157)股价上升9.091%,现价港币$3.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2419424346","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2419424346?lang=zh_cn&edition=full","pubTime":"2024-03-14 14:35","pubTimestamp":1710398100,"startTime":"0","endTime":"0","summary":"[上升股]乐普生物-B(02157) 股价在下午02:35比前收市价上升9.091%,现股价为港币$3.6。至目前为止,今日最高价为$3.6,而最低价为$3.37。总成交量为219.318万股,总成交金额为港币$772.2万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2403142149/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2419697267","title":"乐普生物-B盘中异动 股价大涨6.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419697267","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419697267?lang=zh_cn&edition=full","pubTime":"2024-03-14 09:30","pubTimestamp":1710379809,"startTime":"0","endTime":"0","summary":"2024年03月14日早盘09时30分,乐普生物-B股票出现异动,股价快速拉升6.36%。截至发稿,该股报3.510港元/股,成交量5.6万股,换手率0.00%,振幅1.52%。乐普生物-B股票所在的生物技术行业中,整体涨幅为2.14%。其相关个股中,泰格医药、加科思-B、荣昌生物涨幅较大,振幅较大的相关个股有科济药业-B、加科思-B、百济神州,振幅分别为6.17%、5.98%、4.44%。乐普生物-B公司简介:乐普生物科技股份有限公司是一家专注于肿瘤治疗领域的中国生物制药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140930097a4c7d37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140930097a4c7d37&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419524794","title":"乐普生物-B(02157)下跌5.26%,报3.24元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419524794","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419524794?lang=zh_cn&edition=full","pubTime":"2024-03-13 14:03","pubTimestamp":1710309835,"startTime":"0","endTime":"0","summary":"3月13日,乐普生物-B(02157)盘中下跌5.26%,截至14:03,报3.24元/股,成交260.14万元。乐普生物科技股份有限公司是一家专注于肿瘤治疗领域的创新型生物制药企业,主要通过自主创新和战略合作构建有市场差异化的生物药产品管线,并致力于建立并加强自主生产能力,实现产品的国内商业化和国际市场推广。截至2023年中报,乐普生物-B营业总收入1.54亿元、净利润-1.42亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/13140339833005.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419952147","title":"乐普生物-B盘中异动 急速跳水5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419952147","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419952147?lang=zh_cn&edition=full","pubTime":"2024-03-13 14:03","pubTimestamp":1710309828,"startTime":"0","endTime":"0","summary":"2024年03月13日下午盘14时03分,乐普生物-B股票出现波动,股价大幅下挫5.26%。截至发稿,该股报3.241港元/股,成交量78.2万股,换手率0.05%,振幅8.48%。乐普生物-B股票所在的生物技术行业中,整体跌幅为0.06%。乐普生物-B公司简介:乐普生物科技股份有限公司是一家专注于肿瘤治疗领域的中国生物制药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403131403497a4c33c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403131403497a4c33c3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418323965","title":"乐普生物-B盘中异动 早盘大幅上涨5.92%报3.581港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418323965","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418323965?lang=zh_cn&edition=full","pubTime":"2024-03-12 09:47","pubTimestamp":1710208048,"startTime":"0","endTime":"0","summary":"2024年03月12日早盘09时47分,乐普生物-B股票出现异动,股价大幅拉升5.92%。截至发稿,该股报3.581港元/股,成交量30.6万股,换手率0.02%,振幅6.51%。资金方面,该股资金流入50.197万港元,流出42.497万港元。乐普生物-B股票所在的生物技术行业中,整体涨幅为0.95%。其相关个股中,宜明昂科-B、嘉和生物-B、欧康维视生物-B涨幅较大,振幅较大的相关个股有宜明昂科-B、基石药业-B、欧康维视生物-B,振幅分别为11.27%、8.42%、8.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240312094728861dd43e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240312094728861dd43e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418827008","title":"乐普生物-B(02157.HK)MRG004A获FDA快速通道资格,孤儿药认证提升治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2418827008","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2418827008?lang=zh_cn&edition=full","pubTime":"2024-03-11 08:57","pubTimestamp":1710118671,"startTime":"0","endTime":"0","summary":"【乐普生物-B的MRG004A药物获FDA快速通道资格,为治疗提供新希望。该药物是一种新型靶向组织因子的特异性抗体药物偶联物,用于治疗相关疾病。此次资格认定,为MRG004A的临床开发提供了加速审评的可能性。MRG004A之前已获得FDA的孤儿药资格认证。孤儿药认证通常授予那些针对罕见病治疗效果有显著提升的药物。公司将继续推进MRG004A的临床开发,以期满足患者的需求,同时为公司带来潜在的商业价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403110902308b21ffac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403110902308b21ffac&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418822920","title":"乐普生物-B(02157.HK)治疗胰腺癌候选药物获美国授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2418822920","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2418822920?lang=zh_cn&edition=full","pubTime":"2024-03-11 08:48","pubTimestamp":1710118080,"startTime":"0","endTime":"0","summary":"乐普生物-B(02157.HK) 公布,其候选药物MRG004A (一种新型靶向组织因子的特异性抗体药物偶联物),已获美国食品药品监督管理局(FDA)授予快速通道资格(FTD),用于治疗胰腺癌。MRG004A是一种新型靶向组织因子的特异性抗体药物偶联物,目前在美国及中国进行I/II期临床研究。公司已观察到胰腺癌、三阴性乳腺癌及宫颈癌的抗肿瘤活性信号。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-08 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220330162716458_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220330162716458_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1332163/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2418824050","title":"【港股通】乐普生物-B(02157)MRG004A用于治疗胰腺癌获FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2418824050","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2418824050?lang=zh_cn&edition=full","pubTime":"2024-03-11 08:37","pubTimestamp":1710117461,"startTime":"0","endTime":"0","summary":"金吾财讯 | 乐普生物-B(02157)宣布,公司的候选药物MRG004A(一种新型靶向组织因子的特异性抗体药物偶联物)已获美国食品药品监督管理局(“FDA”)授予快速通道资格(“FTD”),用于治疗胰腺癌。MRG004A是一种新型靶向组织因子的特异性抗体药物偶联物。公司目前在美国及中国进行I/II期临床研究。公司已观察到胰腺癌、三阴性乳腺癌及宫颈癌的抗肿瘤活性信号。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NzBjNjFmNjI4ZDIyNTQ0NjcwODk0MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NzBjNjFmNjI4ZDIyNTQ0NjcwODk0MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1932963","is_publish_highlight":false,"gpt_icon":0},{"id":"2418821327","title":"乐普生物-B(02157):MRG004A 用于治疗胰腺癌获FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2418821327","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2418821327?lang=zh_cn&edition=full","pubTime":"2024-03-11 08:09","pubTimestamp":1710115795,"startTime":"0","endTime":"0","summary":"智通财经APP讯,乐普生物-B 公布,该公司的候选药物MRG004A已获美国食品药品监督管理局授予快速通道资格,用于治疗胰腺癌。据悉,FTD的设立旨在促进和加快药物的临床开发与审评过程,以期满足严重或危及生命的疾病的未被满足的医疗需求。根据相关规定,获得FTD资格的候选药物意味着其有机会通过各种形式加快审评进程。集团已观察到胰腺癌、三阴性乳腺癌及宫颈癌的抗肿瘤活性信号。本次MRG004A获得FTD是继获得FDA授予ODD不久后该公司的又一里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403110811218b21da5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403110811218b21da5a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417285904","title":"乐普生物-B盘中异动 股价大涨5.23%报3.421港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417285904","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417285904?lang=zh_cn&edition=full","pubTime":"2024-03-06 11:22","pubTimestamp":1709695368,"startTime":"0","endTime":"0","summary":"2024年03月06日早盘11时22分,乐普生物-B股票出现波动,股价急速上涨5.23%。截至发稿,该股报3.421港元/股,成交量36.9万股,换手率0.02%,振幅7.69%。资金方面,该股资金流入79.897万港元,流出30.254万港元。乐普生物-B股票所在的生物技术行业中,整体涨幅为0.34%。乐普生物-B公司简介:乐普生物科技股份有限公司是一家专注于肿瘤治疗领域的中国生物制药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030611224887e76564&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030611224887e76564&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417692450","title":"乐普生物-B(02157)股价下跌8.215%,现价港币$3.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2417692450","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2417692450?lang=zh_cn&edition=full","pubTime":"2024-03-05 15:39","pubTimestamp":1709624340,"startTime":"0","endTime":"0","summary":"[下跌股]乐普生物-B(02157) 股价在下午03:39比前收市价下跌8.215%,现股价为港币$3.24。至目前为止,今日最高价为$3.56,而最低价为$3.24。总成交量为118.6万股,总成交金额为港币$397.249万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2403054340/aamm-all-category","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lepubiopharma.com","stockEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.2065},{"period":"3month","weight":-0.2423},{"period":"6month","weight":-0.1605},{"period":"1year","weight":-0.3981},{"period":"ytd","weight":-0.2423}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"exchange":"SEHK","name":"乐普生物-B","nameEN":"LEPU BIO-B"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"乐普生物-B(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供乐普生物-B(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"乐普生物-B,02157,乐普生物-B股票,乐普生物-B股票老虎,乐普生物-B股票老虎国际,乐普生物-B行情,乐普生物-B股票行情,乐普生物-B股价,乐普生物-B股市,乐普生物-B股票价格,乐普生物-B股票交易,乐普生物-B股票购买,乐普生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"乐普生物-B(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供乐普生物-B(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}